Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech reports a 69% Overall Response Rate for its EVX-01 cancer vaccine in a phase 2 trial, with 15 out of 16 melanoma patients experiencing tumor reduction. The promising results of the AI-designed personalized vaccine were presented at the ESMO congress, highlighting Evaxion’s AI-Immunology platform’s potential to enhance treatment efficacy and improve patient outcomes.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
